PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
Approximately 49,200 people are diagnosed with lung cancer every year in the UK. Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma. BeiGene’s Tevimbra recommended by CHMP for gastric and oesophageal cancer. J&J’s Darzalex regimen approved by EC for newly diagnosed multiple myeloma.
AstraZeneca’s sipavibart shown to prevent COVID-19 in …
May 16, 2024 · AstraZeneca (AZ) has shared positive results from a late-stage study evaluating the efficacy of its investigational long-acting monoclonal antibody, sipavibart, in preventing COVID-19 in immunocompromised individuals. Despite accounting for approximately 4% of the population, immunocompromised patients make up about 25% of COVID-19 ...
PME - PMLiVE
Pharmaceutical Market Europe – October 2023. Launch excellence – adapting to data disruption; preparing for the clinical trials of the future; the impact of cell therapies on cancer treatments. 1. 2.
PME - Articles - Pharmaceutical Market Europe
Sep 11, 2024 · PME - Articles. TL STRADOO - Digital biomarkers: reinventing patient monitoring and care. 11 September 2024 Communique - Marketing & Comms. Read More. GLOBAL HEALTH - Causes That Count, Health’ report – key issues affecting global health. 11 September 2024 Communique - Marketing & Comms. Read More.
2023 PM Society Awards – winners announced - PMLiVE
2023 PM Society Awards – winners announced. The PM Society’s 37th annual awards was held on 17 March 2023 at the JW Marriott Grosvenor House London when the industry came together to celebrate the best creative communications in pharma and healthcare. PM Society Co-Chair Caroline Benson kicked off the afternoon, with charity Duchenne UK ...
PME - Magazine Issues
Oct 16, 2024 · PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts.
Merck’s Keytruda shows promise as perioperative head and neck …
Oct 9, 2024 · Merck & Co – known as MSD outside the US and Canada – has shared positive results from a late-stage study of its anti-PD-1 therapy in head and neck cancer. The phase 3 KEYNOTE-689 trial has been evaluating Keytruda (pembrolizumab) as a perioperative treatment for patients newly diagnosed with stage 3 or 4A, resected, locally advanced head ...
PME - Home
A listing of the top 40 creative agencies working on advertising, branding, creative and design projects in the UK healthcare sector. PME – Pharmaceutical Market Europe is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to ...
Merck’s adult-specific pneumococcal vaccine Capvaxive ... - PMLiVE
Jun 19, 2024 · Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) for its adult-specific 21-valent pneumococcal conjugate vaccine. Capvaxive is now authorised to prevent invasive pneumococcal disease and pneumococcal pneumonia in individuals aged 18 years and older. Diseases caused by ...
Biogen shares promising results for higher dose nusinersen in …
Sep 5, 2024 · The neuromuscular disease affects approximately one in every 10,000 babies worldwide. Biogen has shared positive top-line results from a phase 2/3 study evaluating a higher dose regimen of its antisense oligonucleotide nusinersen in spinal muscular atrophy (SMA). The drug is already approved in more than 71 countries under the brand name ...